Earnings Releases·Nov 13, 2026, 4:51 PM ET

Cerenome — Third Quarter 2026 Earnings Summary

Reported first-quarter net diagnostic revenue of $0.7 million versus $0 in the prior year period, resulting in an operating loss of $7.5 million and a net loss of $8.7 million ($1.14 per share) compared to $4.5 million and $4.4 million respectively a year earlier.
Cash and investments declined to $4.9 million as of September 30, 2026, from $8.6 million in June 2026, though the company secured a senior secured financing facility up to $20 million in September and raised an additional $3.8 million via Equity Distribution Agreement post-quarter.
CNSide payer coverage expanded to approximately 190 million covered lives with new in-network agreements including Aetna, while REYOBIQ Phase 2 enrollment completed in October and interim ReSPECT-LM data showed no dose-limiting toxicities.
Outlook remains focused on achieving Medicare reimbursement in the first half of 2027, with topline data expected from ReSPECT-GBM and ReSPECT-LM trials in mid-2027.